Edition:
United States

Avid Bioservices Inc (CDMO.OQ)

CDMO.OQ on NASDAQ Stock Exchange Capital Market

2.40USD
11:57am EST
Change (% chg)

$-0.07 (-2.83%)
Prev Close
$2.47
Open
$2.46
Day's High
$2.46
Day's Low
$2.39
Volume
38,525
Avg. Vol
62,998
52-wk High
$5.77
52-wk Low
$2.25

Latest Key Developments (Source: Significant Developments)

Avid Bioservices Announces Pricing Of Public Offering
Thursday, 15 Feb 2018 05:00am EST 

Feb 15 (Reuters) - Avid Bioservices Inc ::AVID BIOSERVICES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.00 MILLION COMMON SHARES PRICED AT $2.25PER SHARE.SAYS PUBLIC OFFERING OF 9.00 MILLION COMMON SHARES PRICED AT $2.25PER SHARE.  Full Article

Avid Bioservices Announces Proposed Offering Of Common Stock
Wednesday, 14 Feb 2018 04:02pm EST 

Feb 14 (Reuters) - Avid Bioservices Inc ::AVID BIOSERVICES ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.AVID BIOSERVICES INC - ‍INTENDS TO USE NET PROCEEDS FROM OFFERING FOR EXPANSION OF ITS CONTRACT MANUFACTURING BUSINESS AND GENERAL CORPORATE PURPOSES​.  Full Article

Avid Bioservices, Oncologie Enter Into Asset Assignment, Purchase Agreement For Avid's PS-Targeting Program Including Bavituximab
Monday, 12 Feb 2018 08:05am EST 

Feb 12 (Reuters) - Avid Bioservices Inc ::AVID BIOSERVICES AND ONCOLOGIE ENTER INTO ASSET ASSIGNMENT AND PURCHASE AGREEMENT FOR AVID’S PS-TARGETING PROGRAM INCLUDING BAVITUXIMAB.AVID BIOSERVICES INC - ‍AVID WILL RECEIVE $8 MILLION IN UPFRONT PAYMENTS FROM ONCOLOGIE PAID OVER A PERIOD OF SIX MONTHS FROM EXECUTION DATE OF AGREEMENT​.AVID BIOSERVICES INC - ‍AVID WILL BE ELIGIBLE TO RECEIVE UP TO $95 MILLION IN DEVELOPMENT, REGULATORY AND COMMERCIALIZATION MILESTONES​.AVID BIOSERVICES - ‍ONCOLOGIE TO BE RESPONSIBLE FOR FUTURE RESEARCH, DEVELOPMENT & COMMERCIALIZATION OF BAVITUXIMAB, RELATED INTELLECTUAL PROPERTY COSTS​.AVID BIOSERVICES INC - ‍ONCOLOGIE WILL ENTER INTO DEAL WITH AVID FOR FUTURE CONTRACT DEVELOPMENT AND MANUFACTURING ACTIVITIES IN SUPPORT OF BAVITUXIMAB​.  Full Article

Peregrine Pharmaceuticals Appoints Roger Lias As President And CEO
Tuesday, 26 Dec 2017 08:05am EST 

Dec 26 (Reuters) - Peregrine Pharmaceuticals Inc ::PEREGRINE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF ROGER J. LIAS, PH.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.PEREGRINE PHARMACEUTICALS INC- LIAS SUCCEEDS STEVEN KING WHO RESIGNED AS PRESIDENT AND CEO.  Full Article

Peregrine Pharma reports Q2 shr loss $0.31
Monday, 11 Dec 2017 04:05pm EST 

Dec 11 (Reuters) - Peregrine Pharmaceuticals Inc ::PEREGRINE PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER OF FISCAL YEAR 2018 AND RECENT DEVELOPMENTS.Q2 LOSS PER SHARE $0.31.- COMPANY MAINTAINS ITS MANUFACTURING REVENUE GUIDANCE FOR FULL FY 2018 OF $50 MILLION - $55 MILLION.- CONSOLIDATED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS WAS $14.1 MILLION OR $0.31 PER SHARE, FOR Q2 OF FY 2018.  Full Article

Peregrine Pharma, Ronin Trading And SW Investment Management Announce Settlement Agreement
Tuesday, 28 Nov 2017 08:05am EST 

Nov 28 (Reuters) - Peregrine Pharmaceuticals Inc ::PEREGRINE PHARMACEUTICALS, RONIN TRADING AND SW INVESTMENT MANAGEMENT ANNOUNCE SETTLEMENT AGREEMENT.PEREGRINE PHARMACEUTICALS - CO, ‍RONIN TRADING, SW INVESTMENT MANAGEMENT ENTERED SETTLEMENT REGARDING COMPOSITION OF PEREGRINE'S BOARD, AMONG OTHERS.PEREGRINE PHARMACEUTICALS - ON NOV 27, DIRECTORS STEVEN KING,CARLTON JOHNSON,ERIC SWARTZ & DAVID POHL TENDERED RESIGNATION IMMEDIATELY FROM BOARD​.PEREGRINE PHARMACEUTICALS - ‍VACANCIES CREATED BY THE DIRECTOR RESIGNATIONS IMMEDIATELY FILLED BY THREE INDIVIDUALS NOMINATED BY RONIN/SWIM.PEREGRINE PHARMACEUTICALS - RONIN/SWIM, WHICH COLLECTIVELY BENEFICIALLY OWNS 9.6 PERCENT OF CO, WITHDREW NOMINATION OF 6 CANDIDATES TO PEREGRINE'S BOARD​.PEREGRINE PHARMACEUTICALS - ‍RONIN/SWIM ALSO AGREED TO SOME STANDSTILL RESTRICTIONS UNTIL DATE THAT IS 30 CALENDAR DAYS AFTER 2018 ANNUAL MEETING.PEREGRINE PHARMACEUTICALS INC - ‍PEREGRINE HAS ALSO AGREED TO RE-NOMINATE A NUMBER OF RONIN/SWIM'S APPOINTEES AT 2018 ANNUAL MEETING OF STOCKHOLDERS​.  Full Article

Ronin Trading and SW Investment Management announce additional nominations to board of Peregrine pharmaceuticals
Friday, 27 Oct 2017 08:30am EDT 

Oct 27 (Reuters) - Peregrine Pharmaceuticals Inc ::Ronin Trading and SW Investment Management announce additional nominations to board of peregrine pharmaceuticals.‍ronin Trading LLC - nominating Richard B. Hancock, Joel Mccomb for election to Peregrine's board at co's 2017 annual meeting of stockholders​.Ronin Trading says reiterates "demand for peregrine to hold 2017 annual meeting without further delay​".‍Ronin Trading - co, SW Investment Management collectively own about 9.6 pct of Peregrine Pharmaceuticals Inc's outstanding shares of common stock​.  Full Article

Ronin Trading, SW Investment Management nominate James Egan to Peregrine Pharmaceuticals Board
Tuesday, 10 Oct 2017 12:59pm EDT 

Oct 10 (Reuters) - Ronin Trading, LLC and SW Investment Management LLC::Ronin Trading and SW Investment Management announce additional nomination to Board of Peregrine Pharmaceuticals.Ronin Trading and SW Investment Management - ‍nomination of James (Jamie) J. Egan, for election to Peregrine's Board at co's 2017 annual meeting.‍Ronin Trading and SW Investment Management say collectively have beneficial ownership of about 8.9% of Peregrine's outstanding shares of common stock​.  Full Article

Peregrine Pharma appoints Roger Lias as Avid Bioservices president
Monday, 11 Sep 2017 08:05am EDT 

Sept 11 (Reuters) - Peregrine Pharmaceuticals Inc ::Peregrine Pharmaceuticals announces appointment of Roger J. Lias, PH.D. as president of Avid Bioservices.Peregrine - ‍Steven King will step down from role as president of Avid on Sept 25 and remain as president and chief executive officer of Peregrine​.  Full Article

Peregrine announces measures to reduce costs, facilitate profitability and strengthen its operations
Friday, 11 Aug 2017 08:30am EDT 

Aug 11 (Reuters) - Peregrine Pharmaceuticals Inc :Peregrine announces measures to reduce costs, facilitate profitability and strengthen its operations.Says ‍anticipated annual cost savings of over $7 million​.Peregrine Pharmaceuticals ‍reduced its overall workforce by 60 employees (or 20%) as part of its series of planned strategic actions to reduce costs​.Peregrine Pharmaceuticals Inc - ‍Company expects more than $7 million in reduced annualized operating expenses beginning in fiscal year 2019​.Peregrine Pharmaceuticals Inc - ‍As part of cost saving initiatives, company reduced Peregrine's research and development personnel by 50% to 11 employees​.Peregrine Pharm - ‍Charge to earnings for personnel reductions will be between $1.1 million and $1.7 million, which is expected to be incurred during Q2 2018​.Peregrine Pharmaceuticals Inc - ‍Expects workforce reductions to result in a net cost savings of between $3.7 million and $4.3 million in fiscal year 2018​.Peregrine Pharmaceuticals - ‍Reduction in workforce part of planned actions while co pursues strategic options for its research and development assets​.Peregrine Pharmaceuticals Inc - ‍Expects workforce reductions to result in over $7 million in reduced annualized operating expenses beginning in 2019​.Peregrine - ‍Personnel supporting avid bioservices CDMO business, was reduced by 20 percent to 184 employees to align operations with reduction in forecasted revenues​.  Full Article